Sort
10,766 grants matching “checkpoint inhibitor”
T cell expressed miR-155 promotes antitumor immunity and immune checkpoint blockade responses in colon cancer through repression of Ship1
$56,974William Weihao Tang · University Of Utah · F30 · FY2024 · CA
Immunology
$56,848Jose R Conejo-Garcia · H. Lee Moffitt Cancer Ctr & Res Inst · P30 · FY2020 · CA
Immunology
$56,844Jose R Conejo-Garcia · H. Lee Moffitt Cancer Ctr & Res Inst · P30 · FY2021 · CA
Identifying Effective Immune Checkpoint Therapy Strategies in Triple Negative Breast Cancer
$56,694Daniel Patrick Hollern · Univ Of North Carolina Chapel Hill · F32 · FY2017 · CA
Mechanisms of Response and Resistance to Immune Checkpoint Inhibitors in Lung Adenocarcinoma
$56,694Katherine Renee Amato Hastings · Yale University · F32 · FY2017 · CA
Membrane-based immunotherapy for triple negative breast cancer- a partnered approach
$56,472Periasamy Selvaraj · Emory University · R01 · FY2018 · CA
Membrane-based immunotherapy for triple negative breast cancer- a partnered approach
$56,472Periasamy Selvaraj · Emory University · R01 · FY2017 · CA
Project 05: Translational Therapeutics (TT)
$56,328David P Carbone · Ohio State University · P30 · FY2022 · CA
Admin Core
$56,315Elad Ziv · University Of California, San Francisco · P20 · FY2024 · CA
Function of the ATR-ATRIP complex
$56,146David K Cortez · Vanderbilt University · R01 · FY2015 · CA
Development of a novel checkpoint inhibitor-TGF beta combination therapy to reverse immune suppression and increase survival rates in advanced colorectal cancer patients
$56,070Dori A Thomas-Karyat · Synthis Therapeutics, Inc. · R43 · FY2019 · CA
SynerGel: A Novel Tumor Microenvironment-Modulating Hydrogel for Local Immunotherapy
$55,779Simon Young · University Of Texas Hlth Sci Ctr Houston · R01 · FY2022 · DE
Hematologic Malignancies
$55,542Ronald Levy · Stanford University · P30 · FY2022 · CA
Hematologic Malignancies
$55,542Ronald Levy · Stanford University · P30 · FY2023 · CA
Hematologic Malignancies
$55,542Ronald Levy · Stanford University · P30 · FY2024 · CA
In vivo and in vitro roles played by Hdac3 in genomic stability maintenance
$55,310Srividya Bhaskara · Vanderbilt University · F32 · FY2009 · CA
Discovery of protein-protein interaction inhibitors of Replication Protein A
$55,094James Patrone · Vanderbilt University · F32 · FY2014 · CA
GU Malignancies Research Program
$55,093Nima Sharifi · Case Western Reserve University · P30 · FY2022 · CA
Developmental Therapeutics Research Program
$55,090John James Letterio · Case Western Reserve University · P30 · FY2022 · CA
A novel dual-carrier ultrasmall nanomedicine for the treatment of stroma-rich pancreatic cancer
$55,000Katherine Marie Eichinger · Duo Oncology Inc · R41 · FY2024 · CA
Immunology
$54,966Claudio Anasetti · H. Lee Moffitt Cancer Ctr & Res Inst · P30 · FY2019 · CA
Membrane-based immunotherapy for triple negative breast cancer- a partnered approach
$54,778Periasamy Selvaraj · Emory University · R01 · FY2019 · CA
The Oncogenic functions of YAP/TAZ in Renal Cell Carcinoma
$54,538Alec Thomas McIntosh · Georgetown University · F30 · FY2025 · CA
Dissecting the Functional Consequences of Mutations in ZFP36L2 on Tumor Progression and Inflammation in the Tumor Immune Microenvironment of Colorectal Cancer
$54,538Kathleen Luckett · Weill Medical Coll Of Cornell Univ · F30 · FY2025 · CA
Activation of Inflammatory Responses Upon Replication Stress in Basal-Like Breast Cancer
$54,538Elizabeth Frances Gorodetsky · New York University School Of Medicine · F30 · FY2025 · CA